Azevan Pharmaceuticals is a pioneering clinical stage company dedicated to developing cutting-edge pharmaceuticals for Central Nervous System Disorders. Specializing in stress-related CNS disorders and neurodegenerative conditions, Azevan's innovative approach focuses on selectively blocking the effects of arginine vasopressin, a key neurohormone implicated in various disorders. Their lead compound, SRX246, has shown promising results in Phase II clinical trials for Intermittent Explosive Disorder and Huntington's Disease irritability.

Currently, Azevan is conducting an additional Phase II trial for Post-Traumatic Stress Disorder, with a focus on advancing treatment options for these challenging conditions. Azevan's commitment to groundbreaking research and development, along with their collaboration with prestigious institutions like the Department of Defense, showcases their dedication to improving patients' quality of life and addressing unmet medical needs in the field of CNS disorders. Visit Azevan at 116 Research Drive, Bethlehem, PA 18015